# Clinical Cases: Antimicrobials

## Case 1: MRSA Infection and Antibiotic Selection

### Presentation
A 58-year-old man with type 2 diabetes presents with a painful, swollen, erythematous area on his right thigh that began as a small "pimple" 5 days ago. He has fever (38.8°C), and examination reveals a 6 cm fluctuant abscess with surrounding cellulitis. He has no drug allergies. Incision and drainage is performed, revealing purulent material. Gram stain shows gram-positive cocci in clusters. The wound culture grows Staphylococcus aureus that is resistant to oxacillin. Susceptibility testing shows the organism is sensitive to vancomycin, daptomycin, linezolid, and trimethoprim-sulfamethoxazole.

### Clinical Image
![MRSA colony morphology and sensitivity testing](image_01.jpg)
*Antimicrobial susceptibility testing demonstrating the pattern of a methicillin-resistant Staphylococcus aureus (MRSA) isolate with resistance to beta-lactam antibiotics but susceptibility to alternative agents.*

**Image Source**: Lecture image - antimicrobial susceptibility testing

### Questions

1. **What is the mechanism of methicillin (oxacillin) resistance in this organism?**

2. **Why are all beta-lactam antibiotics ineffective against MRSA, regardless of in vitro susceptibility results?**

3. **What are appropriate antibiotic options for this patient, and what factors guide selection?**

4. **If this patient had a severe penicillin allergy (anaphylaxis), how would that affect your antibiotic choice?**

### Answers

1. **Mechanism of methicillin resistance**: MRSA resistance is mediated by the **mecA gene** (or the related mecC gene), which encodes an altered penicillin-binding protein called **PBP2a** (also known as PBP2'). This modified PBP has low affinity for beta-lactam antibiotics. PBPs are enzymes essential for peptidoglycan cell wall synthesis; normally, beta-lactams inhibit PBPs, leading to defective cell wall synthesis and bacterial death. However, PBP2a can continue to synthesize the cell wall even in the presence of beta-lactam antibiotics because they cannot bind effectively to it. The mecA gene is carried on a mobile genetic element called the **staphylococcal cassette chromosome mec (SCCmec)**.

2. **Why all beta-lactams are ineffective**: The PBP2a protein confers resistance to **all beta-lactam antibiotics**, including penicillins, cephalosporins, and carbapenems, because none of them can bind effectively to this altered target. This is true even if laboratory testing might suggest susceptibility to certain beta-lactams - clinical failures occur because PBP2a can compensate for any PBPs that are inhibited. The exception is the new cephalosporin **ceftaroline**, which was specifically designed to bind PBP2a and is approved for MRSA infections. For this reason, standard beta-lactams should never be used to treat MRSA infections.

3. **Appropriate antibiotic options**:
   - **For uncomplicated skin abscess after I&D**: Oral therapy is often adequate. Options include:
     - **TMP-SMX** (first-line for community-acquired MRSA skin infections)
     - **Doxycycline**
     - **Clindamycin** (if susceptible - check for inducible resistance with D-test)
   - **For more severe infections** (extensive cellulitis, systemic symptoms, or failed outpatient therapy):
     - **Vancomycin IV** - first-line for serious MRSA infections
     - **Daptomycin** - alternative, especially for bacteremia
     - **Linezolid** - oral bioavailability is excellent; useful for step-down therapy

   Selection factors include: severity of infection, need for IV vs. oral therapy, renal function, local resistance patterns, and cost.

4. **Effect of severe penicillin allergy**: While beta-lactams are typically avoided in patients with severe penicillin allergy (anaphylaxis), this is actually **not clinically relevant for MRSA infections** because beta-lactams wouldn't work anyway due to the mecA-mediated resistance. The patient can safely receive vancomycin, daptomycin, linezolid, or TMP-SMX, none of which are beta-lactams and therefore pose no cross-reactivity risk. For MSSA infections in penicillin-allergic patients, options include vancomycin or, for non-IgE-mediated reactions, careful cephalosporin use (cross-reactivity is <2% with cephalosporins, particularly those with dissimilar side chains).

---

## Case 2: Aminoglycoside Toxicity

### Presentation
A 72-year-old woman with a prosthetic aortic valve is admitted with fever and positive blood cultures growing Enterococcus faecalis. She is started on ampicillin plus gentamicin for synergistic bactericidal therapy for presumed infective endocarditis. Baseline audiometry is performed. After 10 days of therapy, she reports new onset of tinnitus and difficulty hearing her family members during visits. Repeat audiometry shows bilateral high-frequency hearing loss. Her serum creatinine has also risen from 0.9 mg/dL at admission to 1.8 mg/dL.

### Clinical Image
![Aminoglycoside mechanism and toxicity](image_02.png)
*Diagram illustrating the mechanism of aminoglycoside action (binding to 30S ribosomal subunit causing protein mistranslation) and the mechanisms of ototoxicity and nephrotoxicity.*

**Image Source**: Lecture image - aminoglycoside pharmacology

### Questions

1. **Why is ampicillin combined with an aminoglycoside for enterococcal endocarditis?**

2. **What is the mechanism of aminoglycoside ototoxicity?**

3. **What is the mechanism of aminoglycoside nephrotoxicity, and what are its clinical characteristics?**

4. **How should this patient's antibiotic regimen be modified?**

### Answers

1. **Rationale for combination therapy**: Enterococci are inherently tolerant to beta-lactam antibiotics - ampicillin inhibits cell wall synthesis and is bacteriostatic, but it does not kill enterococci. For serious enterococcal infections like endocarditis, **bactericidal therapy is required** to eradicate the infection from the valve vegetation. The combination of a cell wall-active agent (ampicillin) plus an aminoglycoside (gentamicin or streptomycin) achieves **synergistic bactericidal activity**. The mechanism is that the cell wall damage from ampicillin allows increased aminoglycoside uptake into the bacterial cell, where it causes lethal mistranslation of proteins. This synergism does not occur if the enterococcus has high-level aminoglycoside resistance (HLAR), which must be tested before initiating combination therapy.

2. **Mechanism of ototoxicity**: Aminoglycoside ototoxicity results from **damage to the hair cells** of the cochlea (causing hearing loss) and vestibular apparatus (causing vertigo and imbalance). Aminoglycosides are taken up by hair cells and persist in the inner ear long after serum levels decline. The drugs cause:
   - **Formation of reactive oxygen species (ROS)**
   - **Disruption of mitochondrial function** in hair cells
   - **Activation of apoptotic pathways** leading to irreversible hair cell death

   Hearing loss typically begins in the **high-frequency range** (perceived first as difficulty understanding speech) and progresses to lower frequencies with continued exposure. A mitochondrial DNA mutation (A1555G) markedly increases susceptibility to aminoglycoside ototoxicity.

3. **Mechanism of nephrotoxicity**: Aminoglycosides are freely filtered at the glomerulus and accumulate in **proximal tubular epithelial cells** via megalin-mediated endocytosis. Intracellular accumulation leads to:
   - Disruption of phospholipid metabolism
   - Mitochondrial dysfunction
   - Proximal tubular cell necrosis

   Clinical characteristics include:
   - **Nonoliguric acute kidney injury** (urine output is often preserved)
   - Rise in serum creatinine typically after 5-7 days of therapy
   - **Usually reversible** upon drug discontinuation (unlike ototoxicity)
   - Risk factors: prolonged therapy, high trough levels, concurrent nephrotoxins (NSAIDs, contrast), volume depletion, and advanced age

4. **Modification of antibiotic regimen**: Given the documented ototoxicity and nephrotoxicity, **gentamicin should be discontinued**. Options for completing therapy include:
   - **Ampicillin plus ceftriaxone** - this double beta-lactam combination has been shown to be as effective as ampicillin-gentamicin for E. faecalis endocarditis and is now preferred by many experts, especially for patients at high risk of aminoglycoside toxicity
   - If the isolate is susceptible, **daptomycin** may be considered as an alternative (though its use in left-sided endocarditis is controversial)
   - The aminoglycoside should not be restarted due to the irreversible nature of ototoxicity
   - Audiology follow-up and nephrology consultation are warranted

---

## Case 3: Clostridioides difficile Infection After Antibiotic Use

### Presentation
A 68-year-old woman presents with profuse watery diarrhea (8-10 episodes daily), abdominal cramping, and low-grade fever. She was discharged from the hospital 10 days ago after treatment for community-acquired pneumonia with a 5-day course of levofloxacin. Her current medications include a proton pump inhibitor for GERD. Examination reveals diffuse abdominal tenderness without peritoneal signs. Laboratory studies show WBC 18,000/μL with 15% bands, creatinine 1.6 mg/dL (baseline 0.9), and albumin 2.8 g/dL. Stool testing is positive for C. difficile toxin by PCR and enzyme immunoassay for toxin A/B.

### Clinical Image
![C. difficile colitis pseudomembranes](image_03.png)
*Colonoscopic image demonstrating pseudomembranous colitis with characteristic yellow-white plaques adherent to the colonic mucosa, pathognomonic for Clostridioides difficile infection.*

**Image Source**: Lecture image - C. difficile pathology

### Questions

1. **What is the mechanism by which fluoroquinolones predispose to C. difficile infection?**

2. **What factors make this a case of severe or fulminant C. difficile infection?**

3. **What is the appropriate antimicrobial treatment for this patient?**

4. **What strategies can prevent C. difficile infection in hospitalized patients?**

### Answers

1. **Mechanism of fluoroquinolone predisposition**: Fluoroquinolones and other broad-spectrum antibiotics cause **disruption of the normal gut microbiome** (dysbiosis), eliminating bacteria that normally:
   - **Compete with C. difficile** for nutrients and colonization sites
   - Produce **short-chain fatty acids** that inhibit C. difficile growth
   - Maintain **colonization resistance** through various mechanisms

   Fluoroquinolones are particularly associated with CDI because:
   - They have potent activity against normal gut anaerobes
   - A hypervirulent strain (NAP1/BI/027) emerged with **fluoroquinolone resistance**, allowing it to proliferate during fluoroquinolone therapy
   - The elderly and hospitalized populations most likely to receive fluoroquinolones are also at highest CDI risk

   Additional risk factors in this patient include recent hospitalization, advanced age, and PPI use (which reduces gastric acid barrier to ingested spores).

2. **Severity assessment**: This case meets criteria for **severe CDI** based on:
   - **WBC >15,000/μL** (she has 18,000)
   - **Creatinine >1.5 mg/dL or >1.5x baseline** (she has 1.6, which is >1.5x her baseline of 0.9)
   - **Hypoalbuminemia** (albumin 2.8 g/dL)

   Fulminant (previously called severe-complicated) CDI would additionally include hypotension, ileus, megacolon, or need for ICU admission. Prompt recognition of severe CDI is critical because it requires different treatment than non-severe cases.

3. **Appropriate antimicrobial treatment**: For **severe CDI**, current IDSA/SHEA guidelines recommend:
   - **Fidaxomicin 200 mg orally twice daily for 10 days** (preferred) - narrow spectrum, less microbiome disruption, lower recurrence rate
   - OR **Vancomycin 125 mg orally four times daily for 10 days** - also highly effective

   Key points:
   - **Oral vancomycin, NOT IV vancomycin** - IV vancomycin does not reach the colon in therapeutic concentrations
   - **Metronidazole is NOT recommended** for initial treatment of CDI (inferior efficacy, higher failure rates)
   - Discontinue the inciting antibiotic if possible (levofloxacin is already completed)
   - For fulminant CDI, add IV metronidazole to oral vancomycin and consider surgical consultation
   - **Bezlotoxumab** (anti-toxin B monoclonal antibody) can be considered for high recurrence risk

4. **Prevention strategies**:
   - **Antimicrobial stewardship**: Limit unnecessary antibiotic use, especially fluoroquinolones, clindamycin, and broad-spectrum cephalosporins
   - **Hand hygiene**: Soap and water (alcohol-based sanitizers do not kill C. difficile spores)
   - **Contact precautions**: Gown and gloves for contact with CDI patients
   - **Environmental cleaning**: Sporicidal disinfectants (bleach-based) for rooms of CDI patients
   - **Minimize PPI use** when not clearly indicated
   - **Probiotics**: Evidence is mixed; may have modest benefit for primary prevention in high-risk patients
   - **Early isolation**: Isolate patients with diarrhea pending test results